Abstract
In addition to being the first line of defense against pathogenic attack, the immune system seeks out aberrant cells within the body that may become cancerous. In response, precancerous and cancerous cells may exploit immune checkpoint pathways to evade immune detection and destruction. In order to block these tumorigenic cells, novel therapeutics that modulate immune checkpoint signaling have been developed, with some already available and others in clinical trials. Further development of effective therapeutics for use in personalized medicine requires the identification and characterization of a diverse range of immune checkpoint biomarkers. This webinar will explore recent progress and future directions in translational and clinical efforts centered on checkpoint modulators and combination therapies matched to the molecular profile of individual tumors and the genetic background of patients. View the Webinar
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
